The SHROB (Koletsky) rat as a model for metabolic syndrome

Animal Models of Diabetes, Second Edition: Frontiers in Research

Volumn , Issue , 2007, Pages 185-207

  Koletsky, Richard J ^a   Velliquette, Rodney A ^b   Ernsberger, Paul ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952114140     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (78)

1. Abramowsky CR, Aikawa M, Swinehart GL, Snajdar RM. (1984) Spontaneous nephrotic syndrome in a genetic rat model. Am J Pathol 117:400-408.
2. Aitman TJ, Glazier AM, Wallace CA, et al. (1999) Identification of Cd36 (Fat) as an insulinresistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 21:76-83.
3. Angelin B, Karlmar KE. (1979) Adrenal hydroxylations in genetically obese and hypertensive rats. Biochim Biophys Acta 574:344-350.
4. Benetz BA, Khosrof SA, Huang SS, et al. (1996) Age of onset of retinal vascular changes in obese SHR. Invest Ophthalmol Vis Sci 37:S695.
5. Brindley DN, Hales P, Al-Sieni AII, Russell JC. (1992) Sustained decreases in weight and serum insulin, glucose, triacylglycerol and cholesterol in JCR:LA-corpulent rats treated with D-fenfluramine. Br J Pharmacol 105:679-685.
6. Brindley DN, Russell JC. (2002) Animal models of insulin resistance and cardiovascular disease: Some therapeutic approaches using JCR:LA-cp rat. Diabetes Obesity Metab 4:1-10.
7. Buñag RD, Barringer DL. (1988) Obese Zucker rats, though still normotensive, already have impaired chronotropic baroreflexes. Clin Exp Hypertension [A] 10: Suppl 1, 257-262.
8. Chehab FE, Lim ME, Lu RH. (1996) Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12:318-320.
9. Doggrell SA. (2001) Moxonidine: Some controversy. Expert Opin Pharmacother 2:337-350.
10. Ernsberger P, Ishizuka T, Liu S, et al. (1999) Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 288:139-147.
11. Ernsberger P, Koletsky RJ. (1993) Weight cycling and mortality: Support from animal studies. J Am Med Assoc 269:1116.
12. Ernsberger P, Koletsky RJ, Baskin JS, Collins LA. (1996) Consequences of weight cycling in obese spontaneously hypertensive rats. Am J Physiol 270: R864-R872.
13. Ernsberger P, Koletsky RJ, Baskin JS, Foley, M. (1994a) Refeeding hypertension in obese spontaneously hypertensive rats. Hypertension 24:699-705.
14. Ernsberger P, Koletsky RJ, Baskin JZ, Foley M. (1994b) Refeeding hypertension in obese SHR. Hypertension 24:699-705.
15. Ernsberger P, Koletsky RJ, Collins LA. (1994) Lethal consequences of a high-salt diet in obese SHR. Hypertension 24:376.
16. Ernsberger P, Koletsky RJ, Collins LA, Bedol D. (1996) Sympathetic nervous system in saltsensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drugs Ther 10:Suppl 1, 275-282.
17. Ernsberger P, Koletsky RJ, Collins LA, Douglas JG. (1993) Renal angiotensin receptor mapping in obese spontaneously hypertensive rats. Hypertension 21:1039-1045.
18. Ernsberger P, Koletsky RJ, Friedman JE. (1999) Molecular pathology in the obese spontaneous hypertensive Koletsky rat: A model of syndrome X. Ann NY Acad Sci 892:272-288.
19. Ernsberger P, Koletsky RJ, Kilani A, et al. (1998) Effects of weight cycling on urinary catecholamines: Sympathoadrenal role in refeeding hypertension. J Hypertension 16:2001-2005.
20. Ernsberger P, Koletsky RJ, Kline DD, et al. (1999) The SHROB model of syndrome X: Effects of excess dietary sucrose. Ann NY Acad Sci 892:315-318.
21. Ernsberger P, Rao S. (2000) Moxonidine’s antihypertensive actions do not involve a2- adrenergic receptors in radiotelemetered SHR. J Hypertension 18: S234.
22. Ernsberger P, Velliquette RA, Johnson JL, Koletsky RJ. (2005) Improvements in glucose tolerance and insulin resistance following weight loss persist after regain of the lost weight. Obesity Res 13:A53.
23. Folsom AR, French SA, Zheng W, et al. (1996) Weight variability and mortality: The Iowa Women’s Health Study. Int J Obesity 20:704-709.
24. Friedman JE, de Vente JE, Peterson RG, Dohm GL. (1991) Altered expression of muscle glucose transporter GLUT-4 in diabetic fatty Zucker rats (ZDF/Drt-fa). Am J Physiol 261:E782-E788.
25. Friedman JE, Ishizuka T, Liu S, et al. (1997a) Metabolic consequences of a nonsense mutation in the leptin receptor gene (fak) in the obese spontaneously hypertensive Koletsky rat (SHROB). Exp Clin Endocrinol Diabetes 105: (Suppl. 3), 82-84.
26. Friedman JE, Ishizuka T, Liu S, et al. (1997b) Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Physiol 273:E1014-E1023.
27. Friedman JE, Ishizuka T, Liu S, et al. (1998) Antihyperglycemic activity of moxonidine: Metabolic and molecular effects in obese spontaneously hypertensive rats. Blood Press Suppl 3:32-39.
28. Greenhouse DD, Hansen CT, Michaelis OE. (1990) Development of fatty and corpulent rat strains. ILAR News 32:2-4.
29. Huang SS, Khosrof SA, Koletsky RJ, et al. (1995) Characterization of retinal vascular abnormalities in lean and obese spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 22:S129-S131.
30. Iannello S, Campione R, Belfiore F. (1998) Response of insulin, glucagon, lactate, and nonesterified fatty acids to glucose in visceral obesity with and without NIDDM: Relationship to hypertension. Mol Genet Metab 63:214-223.
31. Ishizuka T, Ernsberger P, Liu S, et al. (1998) Phenotypic consequences of a nonsense mutation in the leptin receptor gene (fak) in obese spontaneously hypertensive Koletsky rats (SHROB). J Nutr 128:2299-2306.
32. Jin H, Chen Y-F, Yang R-H, Oparil S. (1989) Atrial natriuretic factor in NaCl-sensitive and NaCl-resistant spontaneously hypertensive rats. Hypertension 14:404-412.
33. Johnson JL, Wan DP, Koletsky RJ, Ernsberger P. (2005) A new rat model of dietary obesity and hypertension. Obesity Res 13:A113-A114.
34. Kasiske BL, Cleary MP, O’Donnell MP, Keane WF. (1985) Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 106:598-604.
35. Kasiske BL, Kalil RS, Ma JZ, et al. (1993) Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138.
36. Kastin AJ, Pan W, Maness LM, et al. (1999) Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor. Peptides 20:1449-1453.
37. Koletsky RJ, Boccia J, Ernsberger P. (1995) Acceleration of renal disease in obese SHR by exacerbation of hypertension. Clin Exp Pharmacol Physiol 22: Suppl 1, S254-S256.
38. Koletsky RJ, Dluhy RG, Crantz FR, Williams GH. (1982) Cortisol suppression test in patients with elevated adrenocorticotropic hormone levels. Ann Intern Med 96:277-280.
39. Koletsky RJ, Ernsberger P. (1992) Obese SHR (Koletsky rat): A model for the interactions between obesity and hypertension. In Genetic Hypertension, ed. Sassard, J. Libbey, London, 373-375.
40. Koletsky RJ, Ernsberger P. (1996) Phenotypic characterization of genetically obese and hypertensive rat strain: SHROB/Kol. Rat Genome 2:10-22.
41. Koletsky RJ, Friedman JE, Ernsberger P. (2001) The obese spontaneously hypertensive rat (SHROB, Koletsky rat): A model of metabolic syndrome X. In Animal Models of Diabetes: A Primer, ed. Sima, AAF, Shafrir, E. Harwood Academic Press, Amsterdam, 143-158.
42. Koletsky RJ, Velliquette RA, Ernsberger P. (2003) The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann NY Acad Sci 1009:251-261.
43. Koletsky S. (1972) New type of spontaneously hypertensive rats with hyperlipemia and endocrine gland defects. In Spontaneous Hypertension: Its Pathogenesis and Complications, ed. Okamoto, K. Igaku Shoin, Tokyo, 194-197.
44. Koletsky S. (1975a) Animal model: Obese hypertensive rat. Am J Pathol 81:463-466.
45. Koletsky, S. (1975b) Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 80:129-142.
46. Koletsky S, Puterman DI. (1976) Effect of low calorie diet on the hyperlipidemia, hypertension, and life span of genetically obese rats. Proc Soc Exp Biol Med 151:368-371.
47. Koletsky S, Puterman DI. (1977) Reduction of atherosclerotic disease in genetically obese rats by low calorie diet. Exp Mol Pathol 26:415-424.
48. Koletsky S, Snajdar RM. (1979) Reduction of vascular disease in genetically obese rats treated for hypertension and hyperlipidemia. Exp Mol Pathol 30:409-419.
49. Khosrof SA, Huang SS, Benetz BA, et al. (1995) Characterization of retinal vascular abnormalities in lean and obese SHR: A new model of type 2 diabetic retinopathy. Invest Ophthalmol Vis Sci 36:S172.
50. Kurtz TW, Montano M, Chan L, Kabra P. (1989) Molecular evidence of genetic heterogeneity in Wistar-Kyoto rats: Implications for research with spontaneously hypertensive rats. Hypertension 13:188-192.
51. Lynn RB, Cao GY, Considine RV, et al. (1996) Autoradiographic localization of leptin binding in the choroid plexus of ob/ob and db/db mice. Biochem Biophys Res Commun 219:884-889.
52. Mark AL, Correia M, Morgan DA, et al. (1999) State-of-the-art lecture: Obesity-induced hypertension: New concepts from the emerging biology of obesity. Hypertension 33:537-541.
53. Motulsky HJ, Ransnas LA. (1987) Fitting curves to data using nonlinear regression: A practical and nonmathematical review. FASEB J 1:365-374.
54. Mukaddam-Daher S, Menaouar A, El Ayoubi R, et al. (2003) Cardiac effects of moxonidine in spontaneously hypertensive obese rats. Ann NY Acad Sci 1009:244-250.
55. O’Dea K, Koletsky S. (1977) Effect of caloric restriction on basal insulin levels and the in vivo lipogenesis and glycogen synthesis from glucose in the Koletsky obese rat. Metabolism 26:763-772.
56. Okamoto K, Aoki K. (1963) Development of a strain of spontaneously hypertensive rats. Jpn Circ J 27:282-293.
57. Rhinehart EK, Kalra SP, Kalra PS. (2004) Neuropeptidergic characterization of the leptin receptor mutated obese Koletsky rat. Regul Pept 119:3-10.
58. Russel JC, Koeslag DG. (1990) Jcr:LA-corpulent rat: A strain with spontaneous vascular and myocardial disease. ILAR News 32:27-32.
59. Schork NJ, Krieger JE, Trolliet MR, et al. (1995) A biometrical genome search in rats reveals the multigenic basis of blood pressure variation. Genome Res 5:164-172.
60. Steiner AA, Dogan MD, Ivanov AI, et al. (2004) A new function of the leptin receptor: Mediation of the recovery from lipopolysaccharide-induced hypothermia. FASEB J 18:1949-1951.
61. Strohl KP, Thomas AJ, St Schlenker EH, et al. (1997) Ventilation and metabolism among rat strains. J Appl Physiol 82:317-323.
62. Sun Z, Ernsberger P. (2005) Profound insulin resistance of PKB (Akt) activation in intraabdominal adipocytes from obese hypertensive SHROB rats. Obesity Res 13:A102.
63. Takaya K, Ogawa Y, Hiraoka J, et al. (1996) Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 14:130-131.
64. Tan E, Butkus A, Koletsky S. (1976) Hepatic cholesterol metabolism in vitro in the obese spontaneously hypertensive, hyperlipemic and atherosclerotic rat. Exp Mol Pathol 25:142-151.
65. Unger RH. (1971) Glucagon and the insulin: Glucagon ratio in diabetes and other catabolic illnesses. Diabetes 20:834-838.
66. Velasquez MT, Abraham AA, Kimmel PL, et al. (1995) Diabetic glomerulopathy in the SHR/N-corpulent rat: Role of dietary carbohydrate in a model of NIDDM. Diabetologia 38:31-38.
67. Velliquette RA, Ernsberger P. (2003a) Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther 307:1104-1111.
68. Velliquette RA, Ernsberger P. (2003b) The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 306:646-657.
69. Velliquette RA, Friedman JE, Shao J, et al. (2005) Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor (gamma) agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 314:422-430.
70. Velliquette RA, Koletsky RJ, Ernsberger P. (2002) Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. Exp Biol Med (Maywood) 227:164-170.
71. Velliquette RA, Kossover R, Previs SF, Ernsberger P. (2006) Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol 372:300-312.
72. Wan DP, Johnson DH, Johnson JL, et al. (2005) Magnetic resonance imaging of visceral and subcutaneous fat distribution in genetic versus dietary obesity. Obesity Res 13:A172.
73. White BD, Corll CB, Porter JR. (1989) The metabolic clearance rate of corticosterone in lean and obese male Zucker rats. Metabolism 38:530-536.
74. Wyss JM, Oparil S, Sripairojthikoon W. (1992) Neuronal control of the kidney: Contribution to hypertension. Can J Physiol Pharmacol 70:759-770.
75. Yamashita T, Murakami T, Iida M, et al. (1997) Leptin receptor of Zucker fatty rat performs reduced signal transduction. Diabetes 46:1077-1080.
76. Yen TT, Shaw WN, Yu PL. (1977) Genetics of obesity in Zucker rats and Koletsky rats. Heredity 38:373-377.
77. Young JB, Landsberg L. (1982) Diet-induced changes in sympathetic nervous system activity: possible implications for obesity and hypertension. J Chronic Dis 35:879-886.
78. Zavaroni I, Bonini L, Fantuzzi M, et al. (1994) Hyperinsulinaemia, obesity, and syndrome X. J Intern Med 235:51-56.